Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

RCTremdesivirplaceboCOVID 19 all comerssome concern
538/521 suggested
  • suggested 32 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

CAP-China (Wang et al.), 2020
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive
  • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).